CRISPR director granted options for 13,000 shares

CRISPR Therapeutics AG director John Greene received a grant of stock options covering 13,000 common shares.

Rhea-AI Filing Summary

CRISPR Therapeutics AG director John Greene received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.

According to the vesting terms, the award vests in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

Insider Trade Summary

Grant/Award: 13,000 shares

Grant/Award 1 txn

Insider Greene John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Key Figures

Stock options granted: 13,000 options Exercise price: $51.84 per share Expiration date: June 5, 2036 +1 more

4 metrics

Stock options granted 13,000 options Grant covering 13,000 underlying common shares

Exercise price $51.84 per share Exercise price for the 13,000-share option award

Expiration date June 5, 2036 Option award expiration date

Vesting schedule 12 monthly installments First vests June 30, 2026; final vests by 2027 Annual Meeting

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Annual Meeting

4 terms

Stock Option (Right to Buy) financial

"security_title is reported as "Stock Option (Right to Buy)" for this grant."

exercise price financial

"The options have an exercise price of $51.84 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options will vest and become exercisable in 12 equal monthly installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting financial

"The last installment vests on the earlier of the one year anniversary or the date of the 2027 Annual Meeting."

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRISPR Therapeutics (CRSP) director John Greene report in this Form 4?

John Greene reported receiving a grant of stock options for 13,000 common shares of CRISPR Therapeutics AG. These options are a compensation award, not an open-market share purchase or sale, and were granted at a specified exercise price with a defined vesting schedule.

How many CRISPR Therapeutics shares are covered by John Greene’s new options?

The option grant covers 13,000 common shares of CRISPR Therapeutics AG. These are derivative securities that give Greene the right to buy shares in the future if he chooses to exercise, subject to vesting and the stated exercise price terms.

What is the exercise price of John Greene’s CRSP stock options?

The options have an exercise price of $51.84 per share. This means Greene can choose to buy CRISPR Therapeutics common shares at $51.84 once the options vest and before they expire, regardless of the market price at that time.

When do John Greene’s CRISPR Therapeutics options vest?

The options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

When do John Greene’s CRSP stock options expire?

The options are scheduled to expire on June 5, 2036. After that date, any unexercised portion of the 13,000-share option award can no longer be exercised, so Greene must exercise vested options before the expiration date to receive shares.

Is John Greene’s Form 4 transaction a market purchase or sale of CRSP shares?

The Form 4 reflects a grant of stock options, not a market purchase or sale. The transaction is coded as an award, meaning Greene received options as compensation, with no reported open-market buying or selling of CRISPR Therapeutics common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greene John

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$51.84	06/05/2026		A		13,000		(1)	06/05/2036	Common Shares	13,000	$0	13,000	D

Explanation of Responses:

1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

	/s/ Elizabeth Ryland Waldinger	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)